We hypothesize that for breast cancer, on one side, treatment with anti-HER3 monoclonal antibodies would reduce the proliferation and migration of cancer cells by blocking stromal NRG1 binding, thus diminishing tumour aggressiveness. The gene discussed is ERBB3; the disease is breast cancer.